Clinical Trial Results:
A Randomized, Open-Label, International Study of Subcutaneous Recombinant Interleukin-2 (rIL-2, Aldesleukin) with and without Concomitant Antiretroviral Therapy in Patients with HIV-1 Infection and CD4+ Cell Counts ≥ 300/mm3: Study of Aldesleukin with and without Antiretroviral Therapy (ESPRIT 002: STALWART)
Summary
|
|
EudraCT number |
2005-001490-95 |
Trial protocol |
GB ES PT DE IT |
Global completion date |
28 Feb 2009
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
22 Jan 2020
|
First version publication date |
22 Jan 2020
|
Other versions |
|
Summary report(s) |
Effects of Intermittent IL-2 Alone or with Peri-Cycle Antiretroviral Therapy in Early HIV Infection: The STALWART Study |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.